Literature DB >> 9823528

Application of a standardized cytomegalovirus antigenemia assay in the management of patients with AIDS.

S M Lipson1, M E Match, A I Toro, M H Kaplan, D H Shepp.   

Abstract

One-hundred twenty AIDS patients, tested by an optimized cytomegalovirus antigenemia (CMV-Ag) assay, were followed over a 6-month period in an attempt to correlate viral (CMV) load with severe CMV organ-specific disease. Among patients available for follow-up, CMV organ-specific disease was present in seven of eight (88%) with pp65 antigen levels > or = 50 cells per 4 x 10(5) polymorphonuclear leukocytes. One-hundred six patients of 107 patients with levels < 50 pp65 reactive cells did not develop CMV organ-specific disease within our 6-month follow-up period. The CMV-Ag assay, as standardized in our clinical setting, served as a marker and predictor of CMV organ-specific disease in our AIDS patient population.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9823528     DOI: 10.1016/s0732-8893(98)00070-4

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  4 in total

1.  Leukocyte stabilization reagent for use in the cytomegalovirus pp65 antigenemia assay.

Authors:  S M Lipson
Journal:  J Clin Microbiol       Date:  1999-08       Impact factor: 5.948

2.  A multisite trial comparing two cytomegalovirus (CMV) pp65 antigenemia test kits, biotest CMV brite and Bartels/Argene CMV antigenemia.

Authors:  K St George; M J Boyd; S M Lipson; D Ferguson; G F Cartmell; L H Falk; C R Rinaldo; M L Landry
Journal:  J Clin Microbiol       Date:  2000-04       Impact factor: 5.948

3.  Leukocyte concentration in the performance of the pp65 antigenemia assay.

Authors:  S M Lipson; P Della-Latta
Journal:  J Clin Microbiol       Date:  2000-08       Impact factor: 5.948

4.  Evaluation of the PrimeCapture CMV DNA detection plate system for detection of cytomegalovirus in clinical specimens.

Authors:  E H Davoli; S M Lipson; M E Match; D H Shepp; J W Morin; D M Curley
Journal:  J Clin Microbiol       Date:  1999-08       Impact factor: 5.948

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.